Showing 7861-7870 of 9904 results for "".
- TNF Blockers Are Not Associated With Poor Pregnancy Outcomeshttps://practicaldermatology.com/news/tnf-blockers-are-not-associated-with-poor-pregnancy-outcomes/2462122/Continuing tumor necrosis factor (TNF) inhibitors during pregnancy is not associated with worse fetal or obstetric outcomes and may reduce the risk of severe maternal infections during pregnancy, according to research presented at ACR Convergence 2023, the American College of Rheumatology&r
- In the Lab With Boston University Melanoma Researcher Deborah Langhttps://practicaldermatology.com/news/in-the-lab-with-boston-university-melanoma-researcher-deborah-lang-phd/2462120/Deborah Lang, PhD, associate professor of dermatology at Boston University Chobanian & Avedisian School of Medicine, received a two-year, $300,000 Discovery Boost Grant from the American Cancer Society (ACS) for her research project “Exploring roles for PAX3 in regulating gene expressio
- Ventyx Biosciences Halts Trial for Experimental Psoriasis Drughttps://practicaldermatology.com/news/ventyx-biosciences-halts-trial-for-experimental-psoriasis-drug/2462116/Ventyx Biosciences has announced it is halting development of an experimental psoriasis drug due to missed internal targets required for it to advance beyond Phase 2, according to the company. The drug, VTX958, had shown acceptable safety and efficacy, and had achevied with its 225 mg B
- ASDS Elects New Board at Annual Membership Meetinghttps://practicaldermatology.com/news/asds-elects-new-board-at-annual-conference/2462114/The American Society for Derm
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</
- Healiva, C4U Join Forces to Develop New Gene Therapy for EBhttps://practicaldermatology.com/news/healiva-c4u-join-forces-to-develop-new-gene-therapy-for-eb/2462106/Healiva SA (Healiva) and C4U Corporation (C4U) have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also known as “butterfly children”. “The collaboration aims to provide
- Nemolizumab Continues to Wow in PNhttps://practicaldermatology.com/news/nemolizumab-shows-continued-promise-in-pn/2462095/Nemolizumab monotherapy significantly and rapidly improves itch and skin lesions in patients with prurigo nodularis, with clinically meaningful improvements seen as early as week four, according to results from the OLYMPIA 2 Trial, which appears in the
- ESMO News: Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%https://practicaldermatology.com/news/esmo-news-major-pathologic-response-to-neoadjuvant-pembrolizumab-in-advanced-melanoma-trial-exceeds-50/2462089/In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other re
- Aquaphor Partners with NBCUniversal and Giselle Blondet for New Campaignhttps://practicaldermatology.com/news/aquaphor-partners-with-nbcuniversal-and-telemundo-personality-giselle-blondet-for-new-campaign/2462084/Aquaphor is partnering with NBCUniversal and Telemundo personality Giselle Blondet to showcase the multiple uses of Aquaphor Baby Healing Ointment across generations. "Aquaphor Baby has been part of our family for many years. What you see is a perfect reflection of my rel
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi